Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Sponsored by Sirion Therapeutics, Inc.
About this trial
Last updated 15 years ago
Study ID
SRFR-001
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
50 to 89 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 15 years ago
What is this trial about?
The purpose of this phase II study is to determine the efficacy of fenretinide in the
treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular
degeneration (AMD).
What are the participation requirements?
Inclusion Criteria
- males or females, 50 to 89 years of age
- must have GA from AMD in one or both eyes
Exclusion Criteria
- GA due to any disease other than AMD (eg, drug-induced)